Acquired Company

Palvella Therapeutics merged with Pieris Pharmaceuticals and began trading on Nasdaq under PVLA on December 16, 2024.

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania Show more

125 Strafford Avenue, Wayne, PA, 19087, United States

Biotechnology

Healthcare

Start AI Chat

Market Cap

1.04B

52 Wk Range

$18.23 - $114.69

Previous Close

$87.84

Open

$112.00

Volume

1,195,009

Day Range

$109.00 - $127.69

Enterprise Value

622.2M

Cash

63.57M

Avg Qtr Burn

-7.878M

Insider Ownership

21.36%

Institutional Own.

86.40%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
QTORIN Rapamycin Details Microcystic Lymphatic Malformations	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
QTORIN Rapamycin Details Cutaneous Venous Malformations	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
QTORIN Rapamycin Details Angiokeratomas	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
QTORIN™ pitavastatin Details Disseminated superficial actinic porokeratosis (DSAP)	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.